NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Jazz Pharmaceuticals plc (JAZZ) Stock Analysis

Jazz Pharmaceuticals plc (JAZZ) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

JAZZ

$246.81

−$0.76 (−0.31%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare JAZZ with… →

JAZZ Key Statistics

As of Sep 4, 2026
Trading
Open
$246.00
Previous Close
$247.57
Day's Range
244.75–249.00
52-Week Range
123.88–266.38
Volume
321.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.36
Valuation
Market Cap
$16.02B
P/E Ratio
16.89
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
9.58
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.96
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.48
EPS (ttm)Profit attributable to each share over the last twelve months.
14.61
Financials (FY)
Revenue (FY)
$4.27B+4.88%
Net Income (FY)
−$356.15M−163.58%
Profit marginThe share of revenue left as profit after all costs and taxes.
20.45%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
64.91M
1-Year Return
+92.79%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
911.92K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

JAZZ Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+45.18%
2025+38.04%
2024+0.12%
2023−22.79%
2022+25.05%
2021−22.81%
2020+10.56%
2019+20.43%
2018−7.94%
2017+23.50%
2016 (partial year)−26.84%

As of September 4, 2026.

JAZZ Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$4.27B−$356.15M−8.3%
2024$4.07B$560.12M13.8%
2023$3.83B$414.83M10.8%
2022$3.66B−$224.06M−6.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$4.27B$3.76B$517.62M−$356.15M−8.3%
2024$4.07B$3.62B$726.63M$560.12M13.8%
2023$3.83B$3.40B$597.58M$414.83M10.8%
2022$3.66B$3.12B$512.27M−$224.06M−6.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

JAZZ Valuation vs Biotechnology Median

Median of 656 stocks
MetricJAZZBiotechnology medianvs median
P/E16.8912.5734% above
P/S ratio3.4815.260.2x the median
Profit margin20.45%0.00%20.4 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Jazz Pharmaceuticals plc (JAZZ) is capitalised at $16.02B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 2,890.

The most recent close on file for JAZZ is $246.81, dated September 4, 2026. That is −$0.76 (−0.31%) against the previous close. The 52-week range on file runs from $123.88 to $266.38. The latest close sits 99.23% above that 52-week low.

Financial Health

In fiscal 2025, Jazz Pharmaceuticals plc reported revenue of $4.27B. That is +4.88% against the prior fiscal year, when revenue was $4.07B. The same year closed with a net loss of $356.15M. Profit margin runs at 20.45%. That is 20.4 percentage points above the Biotechnology median of 0%. Trailing earnings per share are 14.61.

Across the 4 fiscal years on file, revenue moves from $3.66B in 2022 to $4.27B in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

JAZZ trades at a trailing price-to-earnings ratio of 16.89. That is 34.37% above the Biotechnology median of 12.57. The forward P/E on file is 9.58. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.96. The price-to-sales ratio is 3.48. On price-to-sales that is 0.2 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Over the trailing twelve months the price has returned +92.79%. Across 10 years the annualized return works out at +7.40%. The reported beta is 0.36. Annualized volatility over the trailing 10 years is 32.71%.

Growth & Income

No dividend is on file for JAZZ.

2026 is still running; the price is +45.18% year to date. Across the complete calendar years on file, 2025 returned +38.04% and 2021 returned −22.81%. Of the 9 complete calendar years on file, 6 finished higher.

Peer Comparison

Jazz Pharmaceuticals plc (JAZZ) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Jazz Pharmaceuticals plc JAZZ $16.02B 16.9
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Jazz Pharmaceuticals plc trades at a P/E of 16.9.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

Visit website →